U.S. Markets close in 2 hrs 13 mins

Gilead Sciences Falls on Failed Cirrhosis Drug Trial of Selonsertib

Maylan Studart

fell 3.3% to close at $65.40 in Tuesday's trading after announcing its new liver disease drug Selonsertib failed in Phase 3 trials. Selonsertib is an investigational drug taken orally that was expected to treat patients with compensated cirrhosis caused by nonalcoholic steatohepatitis, or NASH, a chronic and progressive liver disease characterized by fat accumulation and inflammation in the liver. The American biotechnology giant said that STELLAR-4, a Phase 3, randomized, double-blind, placebo-controlled study of Selonsertib didn't show tissue improvements in fibrosis without worsening of NASH in patients.